Limei Liu

Limei Liu

Auto-generated profile, based on publicly available information

Limei Liu

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment Cancer Hospital Chongqing University Chongqing 400038 China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2025 in Advanced Science
Verified
Journal Article
Open access
RZRuiyang Zi
Ruiyang Zi
XZXiang Zhao
Xiang Zhao
LLLimei Liu
Limei Liu
YWYijie Wang
Yijie Wang
RZRui Zhang
Rui Zhang
YDYan Dong
Yan Dong
Metabolic reprogramming of tumor cells dynamically reshapes the distribution of nutrients and signals in the tumor microenvironment (TME), affecting intercellular interactions and resulting in metabolic immune suppression. Increased glucose uptake and metabolism are characteristic of many tumors. Meanwhile, the progression of colorectal carcinoma (CRC) relies on lipid metabolism. Therefore, investigating the role of glucolipid metabolic reprogramming on tumor immunity contributes to identifying new targets for immune suppression intervention in CRC. Our previous work demonstrated that SIRT1 is the hub gene involved in glucolipid metabolic conversion in CRC. Here, it is found that upregulated SIRT1 in CRC cells increases Treg functionality by promoting the secretion of CX3CL1. The CX3CL1‐CX3CR1 signaling activated transcription factors SATB1 and BTG2, promoting the differentiation of TCF7 + Treg cells into functionally enhanced TNFRSF9 + Treg cells. Multiplex immunofluorescence (mIHC) analysis of a CRC tissue microarray confirmed the promoting effect of CX3CL1 on Treg infiltration. Additionally, the therapeutic efficacy of CX3CR1 inhibitor monotherapy and combination therapy is validated with the PD‐1 antibody in the humanized subcutaneous CRC mouse model. This study elucidates a potential mechanism that metabolic reprogramming of cancer cells collaborates with subsequent immunosuppression to promote CRC progression.